默沙东:口头报告三款在研 1类新药关键临床数据

动脉网
01 Jun

默沙东在2025年ASCO大会上口头报告了三款1类新药的关键临床数据,包括MK-1084治疗结直肠癌、Zilovertamab vedotin治疗弥漫大B细胞淋巴瘤和Patritumab deruxtecan治疗肺癌的研究进展。其中,Zilovertamab vedotin的II/III期试验数据显示,联合标准治疗对复发或难治性DLBCL患者有一定疗效,但存在不良事件。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10